Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Zoetis Inc. ZTS

Healthcare  —  Drug Manufacturers Specialty & Generic
71.05 0.78 1.11% as of 25 Sep
Market cap
$29.2B
P/E
11.7×
S&P 500 Member Dividend Champion (10y) Revenue Champion (10y) Insider Buys (last 12m)
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Zoetis Inc. (ZTS) Return on invested capital

Zoetis Inc.'s return on invested capital over the twelve months to 30 June 2026 was 19.6%, down 1.3 percentage points from fiscal 2025 (20.9%). Over the past ten years it has ranged from 7.09% (fiscal 2015) to 20.9% (fiscal 2024); the current reading is higher than 91% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 0.00% and above the Healthcare sector median of 0.00%.

Return on invested capital, annual

Annual

Period Return on invested capital Change (points)
FY2025 20.9% (0.07)
FY2024 20.9% 1.66
FY2023 19.3% 0.26
FY2022 19.0% (1.20)
FY2021 20.2% 3.29
FY2020 16.9% 1.34
FY2019 15.6% 0.36
FY2018 15.2% (3.19)
FY2017 18.4% 3.77
FY2016 14.7% 7.56

Against its own ten years

Low 7.09% High 20.9%
Ten-year median 18.4%
Current reading's percentile 91

Return on invested capital against peers

Company Return on invested capital
UTHR United Therapeutics Corporation compare 23.4%
ZTS Zoetis Inc. 19.6%
NBIX Neurocrine Biosciences, Inc. compare 15.0%
RDY Dr. Reddy's Laboratories Ltd compare 5.89%
TEVA Teva Pharmaceutical Industries Ltd. compare 4.58%
TAK Takeda Pharmaceutical Co. compare 2.88%
ELAN Elanco Animal Health Incorporated compare 0.51%
HLN Haleon PLC Sponsored ADR compare 0.00%
VTRS Viatris Inc. compare −0.20%
Drug Manufacturers Specialty & Generic industry median 0.00%
Healthcare sector median 0.00%
Market median 0.00%

What Return on invested capital is

Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.

TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)

The full definition of Return on invested capital →

More on ZTS